Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.96B.
ENTERPRISE VALUE (EV)
$2.96B
Enliven Therapeutics, Inc.
Market Cap
$3.06B
Enterprise Value (EV)
$2.96B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.06B | $2.96B |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | $3.03B |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.07B | $3.15B |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | $2.96B |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | $2.23B |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | $3.20B |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | $2.30B |
| AtriCure, Inc. (ATRC)vs › | $2.80B | $2.70B |
| CareDx, Inc (CDNA)vs › | $3.41B | $3.05B |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | $3.11B |
Market Cap
$3.06B
Total Debt
$0.00
Cash
$98.90M
Enterprise Value
$2.96B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
